209 related articles for article (PubMed ID: 17700557)
21. Pediatric aspects of familial hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.
Daniels SR; Gidding SS; de Ferranti SD;
J Clin Lipidol; 2011 Jun; 5(3 Suppl):S30-7. PubMed ID: 21600527
[No Abstract] [Full Text] [Related]
22. [About: pleiotropic effects of statins in atherosclerosis].
Ambrosi P
Arch Mal Coeur Vaiss; 2005 Dec; 98(12):1263; author reply 1263-5. PubMed ID: 16435610
[No Abstract] [Full Text] [Related]
23. Is LDL-C passed its prime? The emerging role of non-HDL, LDL-P, and ApoB in CHD risk assessment.
Davidson MH
Arterioscler Thromb Vasc Biol; 2008 Sep; 28(9):1582-3. PubMed ID: 18716322
[No Abstract] [Full Text] [Related]
24. Diabetes as a vascular disease. Dyslipidemia as a target.
Plutzky J
Postgrad Med; 2003 Apr; 113(4 Suppl):15-23. PubMed ID: 19667619
[TBL] [Abstract][Full Text] [Related]
25. Regression of atherosclerosis demands low LDL targets and raised HDL levels.
Cardiovasc J Afr; 2008; 19(4):221. PubMed ID: 18776971
[No Abstract] [Full Text] [Related]
26. Statins, cholesterol, and the prevention of coronary heart disease.
Freeman MW
FASEB J; 2006 Feb; 20(2):200-1. PubMed ID: 16449790
[No Abstract] [Full Text] [Related]
27. [Secondary prevention of patients with ischaemic heart disease--the reduction of LDL cholesterol level and the regression of atherosclerosis].
Bárczi G; Merkely B
Lege Artis Med; 2007 Oct; 17(10):675-9. PubMed ID: 19227597
[TBL] [Abstract][Full Text] [Related]
28. Statins and lupus erythematosus.
Noël B
Rheumatology (Oxford); 2004 Mar; 43(3):397-8; author reply 398-9. PubMed ID: 14963215
[No Abstract] [Full Text] [Related]
29. Apolipoprotein A1 and B.
Sniderman AD; Marcovina SM
Clin Lab Med; 2006 Dec; 26(4):733-50. PubMed ID: 17110237
[TBL] [Abstract][Full Text] [Related]
30. Treatment with statins in high-risk patients: relevance of time to titration of dose and adverse outcomes.
Thadani U
Am J Cardiovasc Drugs; 2009; 9(3):211-2; author reply 212. PubMed ID: 19463025
[No Abstract] [Full Text] [Related]
31. Risks and benefits of statins in lupus erythematosus.
Noël B
Arch Intern Med; 2004 Jan; 164(1):107-8. PubMed ID: 14718334
[No Abstract] [Full Text] [Related]
32. Recent corticosteroid use and recent disease activity: independent determinants of coronary heart disease risk factors in systemic lupus erythematosus?
Karp I; Abrahamowicz M; Fortin PR; Pilote L; Neville C; Pineau CA; Esdaile JM
Arthritis Rheum; 2008 Feb; 59(2):169-75. PubMed ID: 18240259
[TBL] [Abstract][Full Text] [Related]
33. Accelerated atherosclerosis, arterial thromboembolism, and preventive strategies in systemic lupus erythematosus.
Mok CC
Scand J Rheumatol; 2006; 35(2):85-95. PubMed ID: 16641040
[TBL] [Abstract][Full Text] [Related]
34. Effects of a 3-month course of rosuvastatin in patients with systemic lupus erythematosus.
de Kruif MD; Limper M; Hansen HR; de Ruiter J; Spek CA; van Gorp EC; ten Berge IJ; Rowshani AT; ten Cate H; Meesters EW
Ann Rheum Dis; 2009 Oct; 68(10):1654. PubMed ID: 19748921
[No Abstract] [Full Text] [Related]
35. Cholesterol and coronary events. The current thinking.
Jones PH
Postgrad Med; 2003 Apr; 113(4 Suppl):5-14. PubMed ID: 19667618
[TBL] [Abstract][Full Text] [Related]
36. Why the overstated beneficial effects of statins do not resolve the cholesterol controversy.
Mascitelli L; Pezzetta F; Goldstein MR
QJM; 2009 Jun; 102(6):435-6. PubMed ID: 19276210
[No Abstract] [Full Text] [Related]
37. [To give or not to give? Towards the indication of CSE inhibitors ("statins")].
Teichert M; Lüer AK; Stichtenoth DO
Med Monatsschr Pharm; 2008 May; 31(5):184-5. PubMed ID: 18552075
[TBL] [Abstract][Full Text] [Related]
38. Cholesterol rethink for high-risk patients.
Med Lett Drugs Ther; 2004 May; 46(1182):37-9. PubMed ID: 15136771
[No Abstract] [Full Text] [Related]
39. Statins continue to be ubiquitous, but increasingly controversial.
Sipkoff M
Manag Care; 2008 Jun; 17(6):21-2. PubMed ID: 18624162
[No Abstract] [Full Text] [Related]
40. Premature coronary heart disease in systemic lupus erythematosus: what risk factors do we understand?
Nikpour M; Gladman DD; Urowitz MB
Lupus; 2013 Oct; 22(12):1243-50. PubMed ID: 24097996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
